Alkermes plc Stock
Alkermes plc Stock
Alkermes plc gained 0.830% compared to yesterday.
Alkermes plc is currently one of the favorites of our community with 17 Buy predictions and no Sell predictions.
As a result the target price of 38 € shows a very positive potential of 57.02% compared to the current price of 24.2 € for Alkermes plc.
Pros and Cons of Alkermes plc in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alkermes plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alkermes plc | 0.830% | -2.439% | -13.669% | -22.078% | 1.695% | -3.942% | 48.148% |
| Icon plc | 1.610% | -6.970% | 9.951% | -49.301% | -44.524% | -56.586% | - |
| Iovance Biotherapeutics Inc. | 2.990% | -21.720% | 59.719% | 5.595% | 46.016% | -46.177% | -88.167% |
| United Therapeutics | 1.490% | 13.960% | 17.057% | 66.336% | 9.853% | 128.307% | 247.704% |
Comments
Alkermes (ALKS) had its price target lowered by Royal Bank Of Canada from $47.00 to $45.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes (ALKS) had its price target raised by Wells Fargo & Company from $37.00 to $43.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes (NASDAQ:ALKS) had its price target raised by analysts at Truist Financial Corporation from $50.00 to $55.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALKS provided by MarketBeat